Background: Advanced glycation end-products (AGEs) – such as the N(epsilon)-carboxy-methyl-lysine,CML) - and the soluble form of receptor for AGEs (sRAGE) have been reported as emerging biomarker in cardiovascular, metabolic and inflammatory diseases. Their behavior in the setting of liver transplantation (LT) is poorly understood. Methods: Seventeen patients undergoing LT were included in a prospective study. CML and sRAGE were determined before LT, after graft reperfusion and 1, 2, 7 ,30 and 90 days after LT. Results: Baseline CML plasma levels decreased after graft reperfusion (15.7±4.6and8.8±2.7 μg/mL, before LT and after graft reperfusion, respec tively) while returned progressively to baseline values during the follow-up (15.1±5.6 μg/mL at 90 days after LT) (ANOVA, p < 0.0001).The plasma levels of sRAGE did not change significantly soon after LT (median: 872, 1277, 1310, 835pg/mL, before LT, after graft reperfusion, 1 and 2 days after LT, respectively), while they decreased from the seventh day after LT and remained constantly low during the follow-up (274,391 and 233pg/mL, respectively 7, 30 and 90 days after OLT ) (ANOVA, p < 0.0001). Conclusions: Our study provides further evidence to the role of the liver in the metabolism and/or clearance o fCML, while the early decline of sRAGE might be accounted for by use of immunosuppressive medication. CML accumulation and decrease of protective titers of sRAGE might account for the negative metabolic impact of immunosuppression in the setting of LT and be of relevance to current clinical practice.
Early increase in N(epsilon)-carboxy-methyl-lysine and decrease in sRAGE plasma values in de novo liver transplantation
De Simone, Paolo;Filipponi, Franco;
2011-01-01
Abstract
Background: Advanced glycation end-products (AGEs) – such as the N(epsilon)-carboxy-methyl-lysine,CML) - and the soluble form of receptor for AGEs (sRAGE) have been reported as emerging biomarker in cardiovascular, metabolic and inflammatory diseases. Their behavior in the setting of liver transplantation (LT) is poorly understood. Methods: Seventeen patients undergoing LT were included in a prospective study. CML and sRAGE were determined before LT, after graft reperfusion and 1, 2, 7 ,30 and 90 days after LT. Results: Baseline CML plasma levels decreased after graft reperfusion (15.7±4.6and8.8±2.7 μg/mL, before LT and after graft reperfusion, respec tively) while returned progressively to baseline values during the follow-up (15.1±5.6 μg/mL at 90 days after LT) (ANOVA, p < 0.0001).The plasma levels of sRAGE did not change significantly soon after LT (median: 872, 1277, 1310, 835pg/mL, before LT, after graft reperfusion, 1 and 2 days after LT, respectively), while they decreased from the seventh day after LT and remained constantly low during the follow-up (274,391 and 233pg/mL, respectively 7, 30 and 90 days after OLT ) (ANOVA, p < 0.0001). Conclusions: Our study provides further evidence to the role of the liver in the metabolism and/or clearance o fCML, while the early decline of sRAGE might be accounted for by use of immunosuppressive medication. CML accumulation and decrease of protective titers of sRAGE might account for the negative metabolic impact of immunosuppression in the setting of LT and be of relevance to current clinical practice.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
